美股异动 | 阿斯利康(AZN.US)涨逾2% 高盛看多股价至99美元

Core Viewpoint - AstraZeneca's stock rose over 2% to $81.99 following positive results from the Baxdrostat clinical trial presented at the 2025 European Society of Cardiology (ESC) annual meeting, indicating significant sales potential in the hypertension treatment market [1] Group 1: Clinical Trial Results - Baxdrostat demonstrated strong efficacy in treating hypertension during the Phase III BaxHTN clinical trial, which could lead to billions in sales opportunities for AstraZeneca [1] - The drug is a highly selective aldosterone synthase inhibitor (ASI) targeting hormones that elevate blood pressure and increase cardiovascular and renal risks [1] Group 2: Market Potential and Approval Timeline - Over 20,000 patients have been enrolled in global clinical trials for Baxdrostat, which includes studies for hypertension, primary aldosteronism, and chronic kidney disease [1] - Baxdrostat is expected to receive regulatory approval in the first half of 2026 in the US and Europe, potentially becoming the first ASI antihypertensive drug on the market [1] Group 3: Analyst Ratings and Price Target - Goldman Sachs has assigned a "Buy" rating to AstraZeneca with a 12-month price target of $99, representing approximately a 23% upside from the stock's closing price of $80.19 [1]